Matthew S. Block

Also affiliated with WinnMed, Cancer Clinic, Mayo Clinic in Arizona, Foundation for Medical Research

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “BRAF V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance)”.

BRAF V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance)

Mayo Clinic Proceedings Innovations Quality & Outcomes(2021)10.1016/j.mayocpiqo.2021.05.003

N/A

0.430DataRank · unranked

5 citations

Minetta C. Liu, Jacob B. Allred, Lori A. Erickson, Kandelaria M. Rumilla, Matthew S. Block +5 more

Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.07.675

N/A

0.406DataRank · unranked

9 citations

Roisin E. O’Cearbhaill, Matthew S. Block, Erika Hamilton, Jason Konner, Keith L. Knutson +5 more

Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma

Cancer Epidemiology Biomarkers & Prevention(2023)10.1158/1055-9965.epi-22-0941

N/A

0.104DataRank · unranked

1 citations

Matthew S. Block, Julie M. Cunningham, Mark E. Sherman, Bryan M. McCauley, Sebastian M. Armasu +20 more

PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction

Oncogene(2023)10.1038/s41388-023-02785-5

N/A

0DataRank · unranked

14 citations

Prabhu Thirusangu, Ling Jin, Yinan Xiao, Christopher L. Pathoulas, Julie K. Staub +8 more

Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.03.027

N/A

0DataRank · unranked

20 citations

Danielle Enserro, Matthew S. Block, Steven Waggoner, Linda Duska, Andrea E. Wahner-Hendrickson +11 more

MOG Antibody–Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use

Neurology Neuroimmunology & Neuroinflammation(2024)10.1212/nxi.0000000000200249

N/A

0DataRank · unranked

14 citations

Hannah Zhao-Fleming, Yong Guo, Nanthaya Tisavipat, John J. Chen, Αναστασία Ζεκερίδου +7 more

Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.05.046

N/A

0DataRank · unranked

39 citations

Michaela E. McGree, Amy L. Weaver, Aminah Jatoi, Nathan K. LeBrasseur, Gretchen Glaser +4 more

Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting

Melanoma Research(2024)10.1097/cmr.0000000000000997

N/A

0DataRank · unranked

3 citations

Svetomir N. Markovic, Robert R. McWilliams, Lisa A. Kottschade, Heather N. Montane, Anastasios Dimou +7 more

A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6010

N/A

0DataRank · unranked

29 citations

Daniela Matei, Panagiotis A. Konstantinopoulos, Matthew S. Block, Andrea Jewell, Stéphanie Gaillard +15 more

Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007661

N/A

0DataRank · unranked

25 citations

Barath Shreeder, James W. Jenkins, Shi H, Purushottam Lamichhane, Kexun Zhou +10 more